About Us

Welcome to our website and thank you for stopping by. We are Bytesnbio ApS.

Bytesnbio ApS - founded in January 2024

It is a bioinformatics CRO, data science and software company that offers expert analyses and data driven insights for biotech and other data heavy industries. We are experienced in drug discovery, multi omics, biostatistics and much more.

Here are some of the areas we focus on:

  • Genetics, Genomics and Human diseases
  • RNA therapeutics, design of screening libraries, predictions and RNA folding
  • Omics and RNAseq
  • Data Science, machine learning and AI
  • Analytics, Dashbords and Data visualization
  • Apps for automation of workflows, AI integration/prompt engineering
  • Financial analytics, stockmarket predictors

We are very interested in learning about your needs and we are ready to help.
Interested in hearing more about us? Book a free meeting here.
Looking foward to our conversation!

Founder and owner,

Tue Fryland, MSc, PhD

Testimonials

What are they saying

Keith Phillips

Vice President Head of Genetic Medicine, Grünenthal Group.

"Tue (from Bytesnbio ApS) helped us implement an oligonucleotide design and automation pipeline for siRNA and ASOs, working with complex chemistries and challenging registration tasks using HELM. Despite the diversity and creativity of our chemistries, Tue delivered a robust and productive solution that has supported our research effectively."

Your testimonial here?

Ms/Mr Head of Research

We would really appreciate a few words from you

Your testimonial here?

Mr/Ms Founder, CEO

We would really appreciate a few words from you

Selected publications

Research Articles

Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats

Experimental Neurology, 2022

PubMed (PMID: 35988699)

The psychiatric risk gene BRD1 modulates mitochondrial biology and co-transcriptional regulation of nuclear-encoded mitochondrial genes

Molecular Psychiatry, 2022

PubMed (PMID: 35941107)

The psychiatric risk gene BRD1 modulates mitochondrial bioenergetics by transcriptional regulation

Molecular Psychiatry, 2022

PubMed (PMID: 35064041)

Reduced Brd1 expression leads to reversible depression-like behaviors and gene-expression changes in female mice

Translational Psychiatry, 2020

PubMed (PMID: 32681022)

Brain proteome changes in female Brd1+/- mice unmask dendritic spine pathology and show enrichment for schizophrenia risk

Neurobiology of Disease, 2019

PubMed (PMID: 30590179)

Dominant-negative SERPING1 variants cause intracellular retention of C1 inhibitor in hereditary angioedema

Journal of Clinical Investigation, 2019

PubMed (PMID: 30398465)

The effect of hypoxia on ZEB1 expression in a mimetic microenvironment of the human cornea

Molecular Vision, 2019

PubMed (PMID: 30144413)

The Schizophrenia-Associated BRD1 Gene Regulates Behavior, Neurotransmission, and Expression of Schizophrenia Risk Enriched Gene Sets in Mice

Biological Psychiatry, 2017

PubMed (PMID: 27837920)

Identification of the BRD1 interaction network and its impact on mental disorder risk

Genome Medicine, 2016

PubMed (PMID: 27142060)

EWS and FUS bind a subset of transcribed genes encoding proteins enriched in RNA regulatory functions

BMC Genomics, 2015

PubMed (PMID: 26573619)

The Schizophrenia and Bipolar Disorder associated BRD1 gene influences transcription by differential regulation of histone acetylation and co-repressor recruitment

Translational Psychiatry, 2012

PubMed (PMID: 22341945)

Further immunohistochemical characterization of BRD1, a new susceptibility gene for schizophrenia and bipolar affective disorder

Brain Research, 2009

PubMed (PMID: 19763615)